FBXO11 silencing impairs downregulation of BCL6 upon IgM treatment. Immunoblot analysis of FBXO11, BCL6, and actin protein expression in a Burkitt lymphoma cell line (Daudi) treated with IgM in the presence or absence of FBXO11 expression. Three different shRNAs (#2, top; #5, middle; #7, bottom) were used to silence FBXO11 expression. Data were quantitated by densitometric analysis, normalized to actin levels, and graphed relative to untreated cells (right). A representative experiment is displayed out of 2 to 3 independent assays that were performed for each shFBXO11.